Skip to main content
Premium Trial:

Request an Annual Quote

District Court Dismisses Shareholders' Lawsuit Against Accelerate Diagnostics

NEW YORK (GenomeWeb) – Accelerate Diagnostics said today that the US District Court for the District of Arizona has granted the company's motion to dismiss a class-action lawsuit filed against it last year.

The lawsuit was filed by plaintiff Brian Rapp in March 2015 on behalf of all persons or entities that purchased securities in the company over an approximately year-long period, and alleged that the company had made false and misleading statements to investors by failing to disclose certain information about its rapid diagnostic platform.

In granting the company's motion today, the court ordered that the action be dismissed with prejudice in its entirety, Accelerate said.

"This was a case that should never have been brought and was utterly without merit," Steve Schatz of Wilson Sonsini, which represented Accelerate Diagnostics, said in a statement.

Accelerate's current flagship system, Accelerate ID/AST, combines gel electro-filtration, fluorescent in situ hybridization, high-speed microscopy, and advanced algorithms to identify microbiological agents in about 90 minutes and antibiotic susceptibility approximately five hours later, according to the company's website.

The system and its first test, the ID/AST Blood Culture Assay, have received CE-IVD marking, and the company has initiated studies to support a submission to the US Food and Drug Administration.

In Friday afternoon trading on Nasdaq, Accelerate's shares were up nearly 8 percent to $15.25.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.